Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M. Forde, Drew M. Pardoll, Jamie E. Chaft et al.|New England Journal of Medicine|2018Cited by 2.1k
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)Tricia R. Cottrell, Janis M. Taube, Elizabeth D. Thompson et al.|Annals of Oncology|2018Cited by 588
Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cellsNatasha Rekhtman, Arthur I. Skoultchi|Genes & Development|1999Cited by 457
Emergence of a High-Plasticity Cell State during Lung Cancer EvolutionNemanja D. Marjanovic, Tuomas Tammela, Matan Hofree et al.|Cancer Cell|2020Cited by 398
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung CancerAdam J. Schoenfeld, Helena A. Yu, Dana Pe’er et al.|Clinical Cancer Research|2020Cited by 381